Detection of Anti-RNA Polymerase III Antibody and Its Association with Clinical Features in Systemic Sclerosis

Μέγεθος: px

Εμφάνιση ξεκινά από τη σελίδα:

Download "Detection of Anti-RNA Polymerase III Antibody and Its Association with Clinical Features in Systemic Sclerosis"

Οὐρβανός Αντωνιάδης
7 χρόνια πριν
Προβολές:

1 CHINESE JOURNAL OF ALLERGY & CLINICAL IMMUNOLOGY RNA Ⅲ * # SSc RNA Ⅲ ARA SSc 135 SSc ARA SSc ARA 8. 9% 12 7 Ⅰ Scl-70 ACA ARA < Rodnan > ARA Scl-70 ACA SSc SSc ARA ARA SSc / RNA Ⅲ R R A Detection of Anti-RNA olymerase III Antibody and Its Association with Clinical Features in Systemic Sclerosis BAI Yi-naHU Chao-junXU DongHOU YongLI Meng-tao ZHAO Jiu-liangSUN Qiu-ning * ZENG Xiao-feng # Department of Rheumatology and Clinical Immunologyeking Union Medical College HospitalChinese Academy of Medical Sciences & eking Union Medical CollegeBeijing China Objective To detect anti-rna polymerase III ARA in sera of SSc patients and to assess its clinical relevance. Methods Immunoblotting assay was used to detect the presence of ARA in sera of 135 Chinese patients with SScwho were prospectively and consecutively enrolled in the study. Association of prevalence of ARA in SSc patients and their clinical characteristics was analyzed. Results ARA was detected in 8. 9% n = 12 of SSc patientsamong whom seven could not detect anti- Scl-70 and anti-centromere antibody ACA. Our series revealed that serum creatinine and blood urea nitrogen level were significantly higher in ARA positive group < Howeverthe association between ARA and clinical features or laboratory findings including modified Rodnan skin scorecardiac pulmonarygastrointestinal or renal involvements were not identified all > Conclusion ARA EULAR Scleroderma Trial and Research GroupEUSTAR 2006BAI01A072008BAI59B I * # zengxiaofeng@ medmail. com. cn 197

2 may be helpful in diagnosing SScespecially for those anti-scl-70 or ACA can not be detected. ARA positive patients have significantly increased creatinine and blood urea nitrogen level. There is no clinical relevance to other clinical or laboratory features between patients with or without ARA. Chinese SSc patients serological features may be different from other races. Key words sclerodermasystemic /complications autoantibodies anti-rna polymerase III antibody Chin J Allergy Clin Immunol SScEURO line immunoassaylia ml SSc 30 min 3 5 min / ANA 1. 5 ml IgG 30 min Ⅰ Scl min / 15 min ACA 1993 Okano 1 RNA Ⅲ anti-rna EUROLineScan polymerase III antibodiesara 5 SSc RNA Ⅲ Scl % Scl ARA 4 48 h SSc 4% ~ 22% SSc ENA-6 2 SSc SSc ACA min IgG 30 min ACA SSc ± SSc ± ~ SSc Rodnan 5 1 ARA ARA RNA III 1 Table n Clinical manifestations of 135 patients with % ARA ARA September2011

3 RNA Ⅲ SSS17. 0 ARA x - ± s / χ 2 t 3 < ARA Scl-70 ACA ± > 135 SSc ARA % Scl % ACA % ARA Scl % ARA ACA Scl-70 5 ARA ACA Scl-70 1 ARA SSc 3 Table 3 ARA Cutaneous sclerosis signs of 135 patients with 8. 3% 3 25% 3 n % 25% % % % ARA / 1 ARA ± μmol /L ± μmol /L < ± 9. 6 mmol /L 5. 0 ± mmol /L < Table Laboratory findings of 135 patients with x ± s ARA ARA mm /h ± ± C mg /L 4. 1 ± ± μmol /L ± ± < mmol /L 7. 9 ± ± < IgG g /L ± ± IgA g /L 2. 2 ± ± IgM g /L 1. 2 ± ± % 73 ± 1 69 ± % ± ± ARA RNA III ARA ARA 92. 7% SSc ARA ± ARA n ARA ARA ARA RNA III Table Measurements of disease progression of 135 patients with n % n ARA ARA ARA RNA III 199

4 ARA ARA SSc 5% ~ 23% SSc SSc ARA SSc ARA ARA 8. 9% 68 Scl-70 7 ARA SSc / ARA SSc 2 9 1Okano YSteen VDMedsger TA Jret al. Autoantibody reactive with RNA polymerase III in SSc J. Ann Intern Med SSc Koenig MDieudé MSenécal JLet al. redictive value 2% ~ 5% SSc of antinuclear autoantibodies The lessons of the systemic 5 65% 9 13 sclerosis autoantibodies J. Autoimmun Rev Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. reliminary criteria for the 9 ARA 13 classification of scleroderma J. ARA SSc Arthritis Rheum LeRoy ECBlack CFleischmajer Ret al. Scleroderma classificationsubsetsand SSc ARA pathogenesis J. J Rheumatol SSc Clements Lachenbruch Seibold Jet al. Inter-and Scl-70 6 intraobserver variability of total skin thickness score ARA SSc modified Rodnan TSS in J. J ARA SSc Rheumatol Cavazzana IAngela Caolo Aet al. Anti-RNA polymerase III antibodies A marker of ARA with rapid onset and skin thickening progression J. Autoimmun Rev Walker UATyndall ACzirják Let al. Geographical variation of disease manifestations in a report from the EULAR Scleroderma Trials and Research SSc EUSTAR group database J. Ann Rheum Dis ARA Scl-70 8Faucher BStein Granel Bet al. Low prevalence of anti-rna polymerase III antibodies in a French scleroderma population anti-rna polymerase III 200 September2011

5 RNA Ⅲ scleroderma J. Eur J Intern Med Bussone GBérezné Aestre Vet al. The scleroderma kidney progress in risk factorstherapyand prevention J. Curr Rheumatol Rep Ho KTReveille JD. The clinical relevance of autoantibodies in scleroderma J. Arthritis Res Ther Grassegger Aohla-Gubo GFrauscher Met al. Autoantibodies in scleroderma clues for clinical evaluationprognosis and pathogenesis J. Wien Med Wochenschr Cepeda EJReveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes clinical indications and relevance J. Curr Opin Rheumatol Nihtyanova SIarker JCBlack CMet al. A longitudinal study of anti-rna polymerase III antibody levels in J. Rheumatol Ceribelli ACavazzana IAiro at el. Anti-RNA polymerase III antibodies as a risk marker for early gastric antral vascular ectasia GAVE in systemic sclerosis J. J Rheumatol Harvey GRButts SRands ALet al. Clinical and serological associations with anti-rna polymerase antibodies in J. Clin Exp Immunol

Σχετικά έγγραφα

Relationship between Connective Tissue Diseases and Thyroid Diseases

Relationship between Connective Tissue Diseases and Thyroid Diseases CHINESE JOURNAL OF ALLERGY & CLINICAL IMMUNOLOGY # * 272129 connective tissue diseasectd 2009 1 2013 4 CTD CTD CTD CTD 780 438 56. 2% 195 25. 0% 85 10. 9% 44 5. 6% SSc 18 2. 3% 286 36. 7% 8. 7% P < 0.